News Moderna drops mRNA jab for CMV after phase 3 fail Moderna has decided to halt the development of its mRNA-1647 vaccine for congenital CMV infections, once touted as a future blockbuster.
News Alector ditches GSK-partnered dementia drug and cuts staff Alector has abandoned latozinemab as a treatment for frontotemporal dementia, four years after GSK licensed the antibody in a $700m upfront deal.
News Ipsen buys ImCheck, adding mid-stage leukaemia drug Ipsen has agreed to buy ImCheck and its anti-BTN3A antibody for acute myeloid leukaemia in a deal that could be worth up to €1bn.
News Takeda builds in cancer with monster $11.4bn Innovent deal Takeda has partnered with China's Innovent for a pair of late-stage cancer therapies, in a deal that includes an upfront payment of $1.2bn.
News UK start-up Procyon has pancreatic cancer test in its sights Procyon is hoping to launch a diagnostic test next year that will be able to detect people at risk of pancreatic cancer from a urine sample.
News Galapagos abandons cell therapy, putting 365 jobs at risk Galapagos' difficult year has continued with a decision to wind down its cell therapy business as it seeks 'transformative' deals for its drugs unit.
Oncology ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o... For years, ADCs have been positioned as an important addition to the oncology toolkit. But, could they eventually replace chemotherapy altogether?
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
